Metal chelators coupled with nanoparticles as potential therapeutic agents for alzheimer's disease

Journal of Nanoneuroscience

Volumn 1, Issue 1, 2009, Pages 42-55

  Liu, Gang ^a   Men, Ping ^a   Perry, George ^b,c   Smith, Mark A ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of San Antonio   (United States)

Author keywords

Alzheimer disease; Chelation therapy; Metal dysregulation; Nanoparticle delivery; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; CHELATING AGENT; CLIOQUINOL; COPPER CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EDETIC ACID; IRON CHELATING AGENT; NANOPARTICLE; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; NANOTECHNOLOGY; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

EID: 64049102869     PISSN: 19390637     EISSN: 19390653     Source Type: Journal    
DOI: 10.1166/jns.2009.005     Document Type: Review

References (142)

1. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J (1998) Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 15:67.
2. Andersen O (2004) Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini-Re views in Medicinal Chemistry 4:11.
3. Anjaneyulu PS, Staros JV (1987) Reactions of N-hydroxysulfosuccinimide active esters. Int J Pept Protein Res 30:117.
4. Arano Y, Matsushima H, Tagawa M, Koizumi M, Endo K, Konishi J, Yokoyama A (1991) A novel bifunctional metabolizable linker for the conjugation of antibodies with radionuclides. Bioconjug Chem 2:71.
5. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI (2000) Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75:1219.
6. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI (2004) Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43:560.
7. Bangs Laboratories Inc.(Fishers, IN) (1999) TechNote #201, Working with Microspheres.
8. Ben-Shachar D, Riederer P, Youdim MB (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57:1609.
9. Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JM, Rowley D, Halliwell B, Cornish A, Hider RC (1985) Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 56:345.
10. Blunk, T, Hochstrasser DF, Sanchez JC, Muller BW, Muller RH (1993) Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14:1382.
11. Bondy SC, Guo-Ross SX, Truong AT (1998) Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res 799:91.
12. Brem H, Walter KA, Tamargo RJ, Olivi A, Langer R (1994) Drug delivery to the brain.Polymeric Site-Specific Pharmacotherapy (Domb AJ, ed), pp 117-139. John Wiley & Sons, New York.
13. Brewer GJ (2005) Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 19:185.
14. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265:1464.
15. Bush AI, Masters CL, Tanzi RE (2003) Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc Natl Acad Sci USA 100:11193.
16. Butterfield DA (1997) Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10:495.
17. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, Perry G (2004) Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimer's Dis 6:165.
18. Casdorph HR (2001) EDTA chelation therapy: efficacy in brain disorders. A Textbook on EDTA Chelation Therapy (Cranton EM, ed), pp 142-163. Hamtpon Roads Publishing Company, Inc., Charlottesville.
19. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304.
20. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 274:23223.
21. Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, Multhaup G, Beyreuther K, Tanzi RE, Masters CL, Bush AI (2000)
22. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol 130:209.
23. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665.
24. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71:621S.
25. Collingwood JF, Mikhaylova A, Davidson M, Batich C, Streit WJ, Terry J, Dobson J (2005) In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J Alzheimers Dis 7:267.
26. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1990) Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res 27:595.
27. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 31:75.
28. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31:327.
29. Crowe A Morgan EH (1994) Effects of chelators on iron uptake and release by the brain in the rat. Neurochem Res 19:71.
30. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI (2000) Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci 920:292.
31. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ (2005) Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm 59:263.
32. Danehy JP Hunter WE (1967) The alkaline decomposition of organic disulfides. II. Alternati ve pathways as determined by structure. J Org Chem 32:2047.
33. Davson H Segal MB (1996) Physiology of the CSF and Blood-Brain Barriers. CRC Press, Boca Raton.
34. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R (1997) A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 138:877.
35. Ehmann WD, Markesberg WR, Alauddin M, Hossain TI, Brubaker EH (1986) Brain trace elements in Alzheimer's disease. Neurotoxicology 7:195.
36. Evans PH (1993) Free radicals in brain metabolism and pathology. Br Med Bull 49:577.
37. Fasman GD, Moore CD (1994) The solubilization of model Alzheimer tangles: reversing the beta-sheet conformation induced by aluminum with silicates. Proc Natl Acad Sci USA 91:11232.
38. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, Betbeder D (1999) Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 291:1017.
39. Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y (2005) Global prevalence of dementia: a Delphi consensus study. The Lancet 366:2112.
40. Finefrock AE, Bush AI, Doraiswamy PM (2003) Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 51:1143.
41. Floor E (2000) Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease. ell Mol Biol (Noisy-le-grand) 46:709.
42. Galey JB, Dumats J, Beck I, Fernandez B, Hocquaux M (1995) N,N′-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an "oxidative stress activatable" iron chelator in vitro. Free Radic Res 22:67.
43. Gassen M, Youdim MB (1997) The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 80:159.
44. Ghiso J, Frangione B (2002) Amyloidosis and Alzheimer's disease. Adv Drug Deliv Rev 54:1539.
45. Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 31:286.
46. Gutteridge JM (1994) Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann NY Acad Sci 738:201.
47. Halliwell B, Gutteridge JMC (1999) Free Radicals in Biology and Medicine, 3rd edn. Oxford University Press.
48. Hebert LE, Beckett LA, Scherr PA, Evans DA (2001) Annual incidence of Alzheimer's disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15:169.
49. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91:3270.
50. Hershko C (1998) Iron chelators for thalassaemia. Br J Haematol 101:399.
51. Hider RC, Hall AD (1991) Clinically useful chelators of tripositive elements. Prog Med Chem 28:41.
52. Hider RC, Porter JB, Singh S (1994) The design of therapeutically useful iron chelators. The Development of Iron Chelators for Clinical Use (Bergeron RJ, Brittenham GM, eds), pp 353-71.CRC, Boca Raton.
53. Hoffbrand AV (1996) Oral iron chelation. Semin Hematol 33:1.
54. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 6:291.
55. Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, Bush AI (1997) Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem 272:26464.
56. Jain KK (2006) Role of nanotechnology in developing new therapies for diseases of the nervous system. Nanomedicine 1:9.
57. Jefferies WA, Food MR, Gabathuler R, Rothenberger S, Yamada T, Yasuhara O, McGeer PL (1996) Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res 712:122.
58. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44:S72.
59. Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, Perugini M, White AR, Cherny RA, Masters CL, Barrow CJ, Collins SJ, Bush AI, Cappai R (2001) Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40:8073.
60. Kaneko Y, Kitamato T, Tateishi J, Yamaguchi K (1989) Ferritin immunohistochemistry as a marker for microglia. Acta Neuropathol 79:129.
61. Kato N, Nakamura M, Uchiyama T (1999) 1-HNMR studies of the reactions of copper(I) and copper(II) with D-penicillamine and glutathione. J Inorg Biochem 75:117.
62. Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 119:758.
63. Kennard ML, Feldman H, Yamada T, Jefferies WA (1996) Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med 2:1230.
64. Klaasen CD (1996) Heavy metals and heavy-metal antagonists. Goodman and Gilman's the Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds), pp 1649-1671. McGra w Hill, New York.
65. Kong S, Liochev S, Fridovich I (1992) Aluminum(III) facilitates the oxidation of NADH by the superoxide anion. Free Radic Biol Med 13:79.
66. Kontoghiorghes GJ (1986) Iron mobilization from ferritin using α-oxohydroxy heteroaromatic chelators. Biochem J 233:299.
67. Kontoghiorghes GJ (1995) New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A Review Analyst 120:845.
68. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2003) In-situ bloodbrain barrier of nanoparticles. Pharm Res 20:1772.
69. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65.
70. Kreuter J (2004) Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J Nanosci Nanotechnol 4:484.
71. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317.
72. Kruck TP, Fisher EA, McLachlan DR (1993) A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate. Clin Pharmacol Ther 53:30.
73. Lee JY, Mook-Jung I, Koh JY (1999) Histochemically reactive zinc in plaques of the Swedish mutant B-amyloid precursor protein transgenic mice. J Neurosci 19:RC10.1.
74. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25:1315.
75. Linder MC, Hazegh-Azam M (1996) Copper biochemistry and molecular biology. Am J Clin Nutr 63:797S.
76. Liu G, Miller SC, Bruenger FW (1996) Efficient synthesis of N-[2-hydroxyethoxy)methyl]-2-alkyl-3-hydroxy-4-pyridinone by a modified Hilbert-Johnson reaction. Synth Commun 26:2681.
77. Liu G, Bruenger FW, Barrios AM, Miller SC (1995a) Synthesis of 2-alkyl-3-hydroxy-4-pyridinone-ribonucleosides, Potential oral iron chelators.Nucleosides Nucleotides 14:1091.
78. Liu G, Miller SC, Bruenger FW (1995b) Synthesis of lipophilic 3-hydroxy-2-methyl-4-pyridinone derivatives.Synth Commun 25:3247.
79. Liu G, Bruenger FW, Miller SC, Arif AM (1998) Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(β- D-ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration.Bioor g Med Chem Letts 8:3077.
80. Liu G, Men P, Perry G, Smith MA (2007) Nanoparticles for the treatment of Alzheimer's disease: the theoretical rationale, present status and future perspectives. Nanomaterials for Medical Diagnosis and Therapy, Nanotechnologies for the Life Sciences (Kumar C, ed), Vol.10, pp 462-520.W iley-VCH.
81. Liu G, Men P, Kenner GH, Miller SC, Bruenger FW (2004) Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics. Nucleosides Nucleotides Nucleic Acids 23:599.
82. Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA (2005) Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 1741:246.
83. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA (2006) Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406:189.
84. Lockman PR, Oyewumi MO, Koziara J, Roder KE, Mumper RJ, Allen DD (2003a) Brain uptake of thiamine-coated nanoparticles. J Control Rel 93:271.
85. Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen DD (2003b) In-vivo and in-vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticle. Pharm Res 20:705.
86. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Munch G (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 267:4171.
87. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594.
88. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158:47.
89. Luo Y, Han Z, Chin SM, Linn S (1994) Three chemically distinct types of oxidants formed by iron-mediated Fenton reactions in the presence of DNA. Proc Natl Acad Sci USA 91:12438.
90. Lynch SG, Fonseca T, Levine SM (2000) A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol (Noisy-le-grand) 46:865.
91. Lynch T, Cherny RA, Bush AI (2000) Oxidative processes in Alzheimer's disease: the role of abeta-metal interactions. Exp Gerontol 35:445.
92. Markesbery WR, Carney JM (1999) Oxidative alternations in Alzheimer's disease. Brain Path 9:133.
93. Markesbery WR, Ehmann WD (1999) Oxidative stress in Alzheimer disease. Alzheimer Disease (Terry RD, Katzman R, Bick KL, Sisodia SS, ed), pp 401-14. Lippincott Williams and Wilkins, Philadelphia.
94. Marlatt MW, Webber KM, Moreira PI, Lee HG, Casadesus G, Honda K, Zhu X, Perry G, Smith MA (2005) Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 12:1137.
95. Martin FJ, Papahadjopoulos D (1982) Irreversible coupling of immunoglobulin fragments to preformed vesicles.J Biol Chem 257:286.
96. Martin FJ, Hubbell WL, Papahadjopoulos D (1981) Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. Biochemistry 20:4229.
97. May PM, Bulman RA (1983) The present status of chelating agents in medicine. Prog Med Chem 20:225.
98. McLachlan DR, Kruck TP, Lukiw WJ, Krishnan SS (1991) Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ 145:793.
99. Michaelis M, Langer K, Arnold S, Doerr HW, Kreuter J, Cinatl J, Jr. (2004) Pharmacological activity of DTPA linked to protein-based drug carrier systems. Biochem Biophys Res Commun 323:1236.
100. Miniño AM, Heron MP, Murphy SL, Kochanek KD (2007) Centers for disease control and prevention national center for health statistics national vital statistics system.Deaths: final data for 2004. Natl Vital Stat Rep 55:1.
101. Muller RH, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy.Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3.
102. Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K (1996) The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 271:1406.
103. Nelson WO, Timothy B, Karpishin TB, Retting SJ, Orvig C (1988) Aluminum and gallium compounds of 3-hydroxy-4-pyridinones: synthesis, characterization, and crystallography of biologically active complexes with unusual hydrogen bonding. Inorg Chem 27:1045.
104. Neufeld EJ (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107:3436.
105. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32:S2 (Suppl).
106. Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739.
107. Olszewer E, Carter JP (2001) EDTA chelation therapy: a retrospective study of 2,870 patients. A Textbook on DETA Chelation Therapy (Cranton EM, ed), second edn., pp 210-24. Hampton Roads Publishing Company, Inc., Charlottesville.
108. Padmanabhan G, Becue I, Smith JA (1989) Clioquinol. Analytical profiles of drug substances (K.Flore y, ed), pp 57-90.Academic Press, New York.
109. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12:54.
110. Perry G, Castellani RJ, Hirai K, Smith MA (1998) Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimer's Dis 1:45.
111. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC (1988) Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.Blood 72:1497.
112. Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC (1990) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76:2389.
113. Prasad KN, Hovland AR, Cole WC, Prasad KC, Nahreini P, Edwards-Prasad J, Andreatta CP (2000) Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol 23:2.
114. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59:972.
115. Ravi Kumar MN (2000) Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 3:234.
116. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gottfries CG (2001) Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12:408.
117. Richardson DR (1999) The therapeutic potential of iron chelators. Expert Opin Investig Drugs 8:2141.
118. Richardson DR, Ponka P (1998) Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 58:299.
119. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685.
120. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, Mallikarjuana NN, Manohar S, Liang HF, Kulkarni AR, Sung HW, Sairam M, Aminabhavi TM (2005) Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Rel 108:193.
121. Sayre LM, Perry G, Smith MA (1999) Redox metals and neurodegenerative disease. Curr Opin Chem Biol 3:220.
122. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74:270.
123. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87:1305.
124. Scorer CA (2001) Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. Drug Discov Today 6:1207.
125. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46:254.
126. Shi Y, Eyring EM, van Eldik R, Liu G, Bruenger FW, Miller SC (1997) Kinetics and mechanisms of Fe(III) complexation by lipophilic 3-hydroxy-2methyl-1(γ-stearoamidopropyl)-4-pyridinone (HMSP). J Bioinorg Chem 2:728.
127. Smith MA (1998) Alzheimer disease. Int Rev Neurobiol 42:1.
128. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866.
129. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. T rends Neurosci 18:172.
130. Staros JV, Wright RW, Swingle DM (1986) Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem 156:220.
131. Struck M, Waldmeier P, Berdoukas V (1993) The treatment of iron overload-Psychiatric implication.Iron in Central Nervous System Disorders (Riederer P, Youdim MBH, eds), pp 189-96. Springer Verlag, Wien.
132. Subramanian ZF, Vanek ZF (2002) Diagnosis and treatment of Wilson's disease. Curr Neurol Neurosci Rep 2:317.
133. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ (2000) Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 852:274.
134. Thompson CM, Markesbery WR, Ehmann WD, Mao YX, Vance DE (1988) Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology 9:1.
135. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT (2004) The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann NY Acad Sci 1035:34.
136. Walshe JM (1956) Penicillamine, a new oral therapy for Wilson's disease. Am J Med 21:487.
137. Walshe JM (1973) Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Quart J Med 42:441.
138. Walshe JM (1982) Treatment of Wilson's disease with trientine (triethylene teramine) dihydrochloride. Lancet 1:643.
139. Ward RJ, Dexter D, Florence A, Aouad F, Hider R, Jenner P, Crichton RR (1995) Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. Biochem Pharmacol 49:1821.
140. Wong SS (1991) Chemistry of Protein Conjugation and Cross-Linking. CRC Press.
141. Yaari R, Corey-Bloom J (2007) Alzheimer's disease.Semin Neurol 27:32.
142. Youdim MBH, Stephenson G, Shachar DB (2004) Ironing iron out in Parkinson's disease and other neurodegenerative disease with iron chelators A lesson form 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci 1012:306.